Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Adagene Inc

Clinical trials sponsored by Adagene Inc, explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New drug duo aims to shrink Hard-to-Treat tumors Results expected Oct 2026 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1 Not yet finished but already full! 1 Completed 1

Experimental antibody ADG206 targets Hard-to-Treat cancers in first human trial

Disease control Ongoing

This early-phase study tests a new drug called ADG206 in 14 people with advanced solid tumors that have not responded to standard treatments. ADG206 is an antibody designed to activate the immune system by targeting CD137, a protein on immune cells. The main goals are to check sa…

Phase 1 • Sponsor: Adagene Inc • Aim: Disease control

Last updated Jun 27, 2026 08:09 UTC